SWOT Analysis for Nektar Therapeutics

MACD Crossover Above Signal Line
Rising Net Cash Flow and Cash from Operating activity
Annual Profit Growth higher than Sector Profit Growth
PEG lower than Industry PEG
Relative Outperformance versus Industry over 1 Week
MACD crossed above signal line previous end of day
Increasing Revenue every quarter for the past 3 quarters
Strong cash generating ability from core business - Improving Cash Flow from operation for last 2 years
Annual Net Profits improving for last 2 years
Increasing profits every quarter for the past 2 quarters
Stock with Low PE (PE < = 10)
Biggest Price Gainers from Open

Promoter decreasing their shareholding
Bearish Stocks - Stocks with Medium to Low Trendlyne Momentum Score
Low DVM Stocks - Stocks to Exercise Caution On
Lowest Momentum Scores (Technical Scores)
Stocks with Expensive Valuations according to the Trendlyne Valuation Score
Low durability companies
Weak Stocks (DVM)
Inefficient use of shareholder funds - ROE declining in the last 2 years
Highest fall from 52 Week High
Top Losers
Low Piotroski Score : Companies with weak financials
Book Value Per Share deteriorating for last 2 years
Weak performer : Stock lost more than 20% in 1 month
Weak Momentum: Price below Short, Medium and Long Term Averages
RSI indicating price weakness
Top Losers
Stocks Underperforming their Industry Price Change in the Quarter